and separates the genes encoding the components necessary for viral packaging onto four different plasmids. These features, in conjunction with several other biosafety enhancements, prevent ...
The rationale behind four plasmids is to enhance safety, as separating genetic components reduces chances of recombination. The ‘transfer plasmid’ or lentiviral vector contains the transgene ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback